Format

Send to

Choose Destination
Trends Biotechnol. 2016 May;34(5):382-393. doi: 10.1016/j.tibtech.2016.01.001. Epub 2016 Feb 3.

Stem Cell-Based Human Blood-Brain Barrier Models for Drug Discovery and Delivery.

Author information

1
Center of Neurosciences and Cell Biology (CNC), University of Coimbra, 3004-517 Coimbra, Portugal; Center of Innovation in Biotechnology (Biocant), 3060-197 Cantanhede, Portugal; Institute for Interdisciplinary Research, University of Coimbra (IIIUC), 3030-789 Coimbra, Portugal.
2
Blood-Brain Barrier Laboratory, Université d'Artois EA 2465, 62307 Lens, France. Electronic address: romeo.cecchelli@univ-artois.fr.
3
Blood-Brain Barrier Laboratory, Université d'Artois EA 2465, 62307 Lens, France.
4
Center of Neurosciences and Cell Biology (CNC), University of Coimbra, 3004-517 Coimbra, Portugal; Center of Innovation in Biotechnology (Biocant), 3060-197 Cantanhede, Portugal; Institute for Interdisciplinary Research, University of Coimbra (IIIUC), 3030-789 Coimbra, Portugal. Electronic address: lino@biocant.pt.

Abstract

The development of novel neuropharmaceuticals requires the evaluation of blood-brain barrier (BBB) permeability and toxicity. Recent studies have highlighted differences in the BBB among different species, with the most important differences involving the expression of P-glycoprotein (P-gp), multidrug resistance-associated proteins, transporters, and claudins. In addition, functional studies have shown that brain pharmacokinetics of P-glycoprotein substrates are different in humans and rodents. Therefore, human BBB models may be an important platform for initial drug screening before in vivo studies. This strategy might help to reduce costs in drug development and failures in clinical studies. We review the differences in the BBB among species, recent advances in the generation of human BBB models, and their applications in drug discovery and delivery.

KEYWORDS:

blood–brain barrier; in vitro models; neurodegenerative diseases; neuropharmaceuticals; stem cells

PMID:
26838094
DOI:
10.1016/j.tibtech.2016.01.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center